HK2 and liver cancer: Depletion of HK2/ROCK2 by shRNA or inhibitors reduces TPC contractility to remodel vasculature, while combined treatment of HK2 inhibitor and doxorubicin enhanced the efficacy of chemotherapy drug against tumor growth in both lung and liver cancer animal models.